Real-world practice & outcomes in mCSPC

Scott Tagawa, MD, MS, Weill Cornell Medicine, New York City, NY, describes the findings of a real-world evidence study evaluating practice patterns and survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) at ASCO GU 2021. Based on US Veterans Health Administration claims data from 1395 patients with mCSPC that initiated treatment between 2014 and 2018, it was found that the majority were treated with androgen deprivation therapy (ADT) alone, despite the emergence of docetaxel and novel hormonal therapies at that time. This interview took place during the 2021 Genitourinary Cancers Symposium.